Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00195689 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
NCT00195689: Completed Phase 3 study, sponsored by Abbott.
NCT00195689 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 400 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00195689, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the long-term safety and clinical efficacy of adalimumab in treatment of moderate to severely active psoriatic arthritis
Interventions
- BIOLOGICAL Human anti-TNF monoclonal antibody/adalimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2003-08 |
| Phase | Phase 3 |
What the finished NCT00195689 record still lists
NCT00195689 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 1 intervention - of which Human anti-TNF monoclonal antibody/adalimumab is the first listed.
NCT00195689 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00195689 about?
NCT00195689 is a clinical study titled "Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis". The purpose of the study is to assess the long-term safety and clinical efficacy of adalimumab in treatment of moderate to severely active psoriatic arthritis
What is the current status of trial NCT00195689?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2003-08.
What interventions are being tested in trial NCT00195689?
The interventions under investigation include: Human anti-TNF monoclonal antibody/adalimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00195689?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00195689's enrollment target sits among peer trials
400 922nd of 2000 higher than 1,039 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia